Recalcitrant Epidermolysis Bullosa Acquisita Treated with Upadacitinib as a Bridge to Rituximab

Authors

Taha F. Rasul, HCA HealthcareFollow
Anthony Concilla, HCA HealthcareFollow
Michelle Militello, HCA HealthcareFollow
Paola Torres
Angelia Stepien, HCA HealthcareFollow

Division

South Atlantic

Hospital

Orange Park Medical Center

Document Type

Case Report

Publication Date

6-25-2025

Keywords

JAK inhibitors, autoimmune blistering disease, bridging therapy, epidermolysis bullosa acquisita, mechanobullous EBA, refractory dermatologic disease, rituximab, Upadacitinib

Disciplines

Dermatology | Immune System Diseases | Medicine and Health Sciences | Skin and Connective Tissue Diseases

Abstract

No abstract available.

Publisher or Conference

JAAD Case Reports

Recommended Citation

Rasul T, Concilla A, Militello M, Torres P, Stepien A. Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab. JAAD Case Rep. 2025;63:34-37. Published 2025 Jun 25. doi:10.1016/j.jdcr.2025.06.022